- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Intensity Therapeutics GAAP EPS of -$0.22 | 2 | Seeking Alpha | ||
| 13.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 26 | PR Newswire | Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated
European Medicines Agency Authorization to initiate INVINCIBLE-4-Study... ► Artikel lesen | |
| 13.05. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 25.04. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | Why Intensity Therapeutics (INTS) Stock Is Getting Hammered | 3 | Benzinga.com | ||
| 25.04. | Intensity Therapeutics plunges on $2.35M public offering | 2 | Seeking Alpha | ||
| 25.04. | Intensity Therapeutics legt Bedingungen für Angebot über 2,35 Millionen US-Dollar fest | 2 | Investing.com Deutsch | ||
| 24.04. | INTENSITY THERAPEUTICS, INC. - S-1/A, General form for registration of securities | 6 | SEC Filings | ||
| 22.04. | INTENSITY THERAPEUTICS, INC. - S-1, General form for registration of securities | 5 | SEC Filings | ||
| 19.03. | Benchmark maintains Speculative Buy on Intensity Therapeutics | 1 | Investing.com | ||
| 13.03. | Intensity Therapeutics GAAP EPS of -$1.17 in-line | 1 | Seeking Alpha | ||
| 13.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update | 487 | PR Newswire | 32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened
Eight Swiss sites are activated in the INVINCIBLE-4 Study, and... ► Artikel lesen | |
| 13.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.01. | Intensity Therapeutics' Sarkom-Studie schreitet nach Überprüfung voran | 4 | Investing.com Deutsch | ||
| 28.01. | Intensity Therapeutics' sarcoma trial proceeds after review | 1 | Investing.com | ||
| 28.01. | Intensity Therapeutics Inc.: Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review | 115 | PR Newswire | INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
| NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 36,800 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| EDITAS MEDICINE | 1,681 | 0,00 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| GINKGO BIOWORKS | 6,550 | -1,50 % | Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer | BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and... ► Artikel lesen | |
| NOVOCURE | 14,450 | -3,12 % | Zai Lab Limited: Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,250 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business Update | TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 2,080 | -1,89 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,471 Euro und damit +10,45 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.